https://www.selleckchem.com/pr....oducts/talabostat.ht
ctDNA was detected in 35 patients (64 %), 22 with high and 13 with low ctDNA levels. Overall, 77 % were positive for TP53, 29 % for KRAS, and 11 % for STK11 mutations, more than one alteration was detected in 43 % of samples. Multivariate analysis showed that positive ctDNA was significantly associated with shorter PFS (HR, 4.31, 95 %CI 2.06-8.99, p 0.0001), and shorter OS (HR, 3.52, 95 %CI 1.72-7.19, p 0.001). Moreover, OS was significantly longer for patients with low ctDNA levels at diagnosis as compared to high (p = 0.0
Like
Comment
Share
